
-
Biogen NasdaqGS:BIIB Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Location: 225 Binney Street, Cambridge, MA, 02142, United States | Website: https://www.biogen.com | Industry: Drug Manufacturers - General | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
23.47B
Cash
2.598B
Avg Qtr Burn
N/A
Short % of Float
2.29%
Insider Ownership
0.22%
Institutional Own.
92.84%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
QALSODY™ BIIB067 (tofersen) Details Amyotrophic lateral sclerosis | Approved Update | |
ADUHELM™ / Aducanumab (Aβ mAb) Details Alzheimer’s disease | Approved Quarterly sales | |
Leqembi (Lecanemab) IV Maintenance Dosing Details Alzheimer's disease | Approved Quarterly sales | |
SKYCLARYS™ (Omavaloxolone) Details Friedreich’s Ataxia | Approved Quarterly sales | |
ZURZUVAE BIIB125 (zuranolone) Details Postpartum depression | Approved Quarterly sales | |
Leqembi (Lecanemab) (Aβ mAb) Details Alzheimer's disease | Approved Quarterly sales | |
TOFIDENCE (BIIB800) (tocilizumab) Details Polyarticular juvenile idiopathic arthritis, Rheumatoid arthritis | Approved Quarterly sales | |
Leqembi (Lecanemab) SC formulation Details Alzheimer's disease | PDUFA Approval decision | |
Felzartamab Details Kidney transplantation, Primary Membranous Nephropathy, IgA nephropathy, Antibody-mediated rejection | Phase 3 Update | |
Dapirolizumab pegol Details Systemic lupus erythematosus | Phase 3 Initiation | |
Nusinersen (SPINRAZA) Details Spinal muscular atrophy | Phase 2/3 Update | |
BIIB124 Details Essential tremor | Phase 2b Data readout | |
BIIB080 (tau ASO) Details Alzheimer's disease | Phase 2 Data readout | |
IONS582 /BIIB121 Details Angelman Syndrome | Phase 1b Data readout | |
BIIB113 Details Alzheimer's disease | Phase 1 Update | |
BIIB093 (IV glibenclamide) Details Acute myocardial infarction | Failed Discontinued | |
SB15 (biosimilar referencing EYLEA®) Details no known indication | Failed Discontinued | |
BIIB074 (vixotrigine) Details no known indication | Failed Discontinued | |
ATXN2 ASO (BIIB105) Details Amyotrophic lateral sclerosis | Failed Discontinued |